5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Neoplasms
Interventions
DRUG

5-Fluoro-2-Deoxycytidine (FdCyd)

Given PO and IV

OTHER

Laboratory Biomarker Analysis

Correlative Studies

OTHER

Pharmacological Study

Correlative Studies

DRUG

Tetrahydrouridine (THU)

Given PO and IV

Trial Locations (4)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

90089

USC/Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope National Medical Center, Duarte

95817

University of California, Davis Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER